Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial

Key Points

Switching to fixed-dose doravirine and islatravir maintains viral suppression in patients with HIV-1.
After 48 weeks, 98% of patients achieved viral load below 50 copies/mL on fixed-dose therapy.
This multicentre, randomised, open-label trial indicates its effectiveness compared to existing regimens.
Finding alternative dosing may simplify treatment for virologically suppressed adults, enhancing adherence.

We only have this paper's title and publication details.

Shows non-inferiority of fixed-dose therapy in virologically suppressed adults, suggesting an effective alternative.

No takes yet. Share an insight, caveat, or question.

Orkin et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share